Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | PPARA | Q07869 | 9/20 | 0.47 |
| ▸ | PPARG | P37231 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clinofibrate SCHEMBL20339978 | 1.00 | ADORA3 (1.00) | ADORA3PPARAPPARGMEN1KMT2A | |
| Clinofibrate SCHEMBL3955329 | 1.00 | ADORA3 (1.00) | ADORA3PPARAPPARGMEN1KMT2A | |
| Clinofibrate SCHEMBL11223466 | 0.99 | ADORA3 (0.97) | ADORA3PPARAPPARGMEN1KMT2A | |
| SCHEMBL12918479 | 0.96 | ADORA3 (0.92) | ADORA3PPARAPPARGMEN1KMT2A | |
| SCHEMBL12918476 | 0.95 | ADORA3 (0.90) | ADORA3PPARAPPARGMEN1KMT2A | |
| SCHEMBL28012863 | 0.95 | ADORA3 (0.90) | ADORA3PPARAPPARGMEN1KMT2A | |
| SCHEMBL12918474 | 0.94 | ADORA3 (0.88) | ADORA3PPARAPPARGMEN1KMT2A | |
| Clinofibrate SCHEMBL7620220 | 0.84 | ADORA3 (0.71) | ADORA3PPARAPPARGMEN1KMT2A | |
| SCHEMBL15682176 | 0.83 | ADORA3 (0.69) | ADORA3PPARAPPARGMEN1KMT2A | |
| SCHEMBL11577248 | 0.82 | ADORA3 (0.70) | ADORA3PPARAPPARGMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6976 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| US-20250367216-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | claimed |
| US-20250367217-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | claimed |
| US-20250269005-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2025-08-28 | — | — | US | claimed |
| US-12377066-B2 | Treatment of diseases associated with biliary system destruction | ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (FR) | 2025-08-05 | — | — | US | claimed |
| US-20250009744-A1 | USE OF METABOLIC REGULATORS FOR THE TREATMENT OF LIPOTOXICITY IN THE LUNGS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2025-01-09 | — | — | US | claimed |
| WO-2024251233-A1 | USE OF PPAR FULL AGONIST IN COMBINATION WITH THR-β AGONIST IN RESISTING OF METABOLIC-RELATED DISEASES | 成都微芯药业有限公司 | 2024-12-12 | — | — | WO | claimed |
| US-20240398789-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTI-TUMOR EFFECT OF EZH2 INHIBITOR AND USE THEREOF | PEKING UNIVERSITY THIRD HOSPITAL (CN) | 2024-12-05 | — | — | US | claimed |
| US-20240374587-A1 | MEDICINE FOR PREVENTION AND TREATMENT OF DISEASES LINKED TO ANTI-OBESITY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2024-11-14 | — | — | US | claimed |
| WO-1998021349-A1 | NOVEL CONSTRUCTS AND VECTORS FOR THE TARGETED AND INDUCIBLE EXPRESSION OF GENES | RHONE-POULENC RORER S.A. (FR) | 1998-05-22 | — | — | WO | claimed |
| WO-1998003069-A1 | METHOD FOR LOWERING SERUM LIPID LEVELS EMPLOYING AN MTP INHIBITOR IN COMBINATION WITH ANOTHER CHOLESTEROL LOWERING DRUG | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-01-29 | — | — | WO | claimed |
| US-5593971-A | ALONE OR IN COMBINAATION WITH ANGIOTENSIN CONVERTING ENZYME INHIBITOR | E. R. SQUIBB & SONS, INC. (US) | 1997-01-14 | — | — | US | claimed |
| EP-0457514-B1 | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor | SQUIBB & SONS INC (US) | 1996-08-21 | — | — | EP | claimed |
| US-5179097-A | Salts of non-steroidal anti-inflammatory carboxylic acids and anti-lipidemic carboxylic acids | ANGRES ISAAC A (US) | 1993-01-12 | — | — | US | claimed |
| EP-0508665-A2 | Use of ACE inhibitors for lowering serum cholesterol | E.R. SQUIBB & SONS, INC. (US) | 1992-10-14 | — | — | EP | claimed |
| EP-0482498-A2 | Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor | E.R. SQUIBB & SONS, INC. (US) | 1992-04-29 | — | — | EP | claimed |
| EP-0475148-A1 | Pravastatin alone or in combination with a fibric acid derivative for preventing onset of or treating type III hyperlipoproteinemia | E.R. SQUIBB & SONS, INC. (US) | 1992-03-18 | — | — | EP | claimed |
| EP-0457514-A1 | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor | E.R. SQUIBB & SONS, INC. (US) | 1991-11-21 | — | — | EP | claimed |
| EP-0455042-A1 | Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination | E.R. SQUIBB & SONS, INC. (US) | 1991-11-06 | — | — | EP | claimed |